15 For '18: Key Clinical Data to Watch For Next Year

Among some of 2018’s most important clinical data are Moderna's experimental mRNA flu vaccines. This year, Moderna reported that its two experimental mRNA flu vaccines were well tolerated. Next year, Moderna plans to publish complete findings from the phase 1 studies of mRNA-1440 and mRNA-1851, meant to protect against the H10N8 and H7N9 flu strains, respectively. Both strains are thought to have pandemic potential